its candidate for an inherited neurological condition called Huntington’s Disease, failed in a mid-stage trial. The 12-week DIMENSION study evaluated how dalzanemdor, also known as SAGE-718 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback